Bempedoic Acid and Cardiovascular Outcomes in Statin-Intolerant Patients.
Steven E NissenA Michael LincoffDanielle BrennanKausik K RayDenise MasonJohn J P KasteleinPaul D ThompsonPeter LibbyLeslie ChoJorge PlutzkyHarold E BaysPatrick M MoriartyVenu MenonDiederick E GrobbeeMichael J LouieChien-Feng ChenNa LiLeAnne BloedonPaula RobinsonMaggie HornerWilliam J SasielaJackie McCluskeyDeborah DaveyPedro Fajardo-CamposPredrag PetrovicJan FedackoWitold ZmudaYury LukyanovStephen J Nichollsnull nullPublished in: The New England journal of medicine (2023)
Among statin-intolerant patients, treatment with bempedoic acid was associated with a lower risk of major adverse cardiovascular events (death from cardiovascular causes, nonfatal myocardial infarction, nonfatal stroke, or coronary revascularization). (Funded by Esperion Therapeutics; CLEAR Outcomes ClinicalTrials.gov number, NCT02993406.).
Keyphrases
- cardiovascular events
- end stage renal disease
- coronary artery disease
- ejection fraction
- cardiovascular disease
- newly diagnosed
- chronic kidney disease
- heart failure
- prognostic factors
- peritoneal dialysis
- coronary artery
- type diabetes
- small molecule
- coronary artery bypass grafting
- acute coronary syndrome
- insulin resistance
- patient reported
- aortic valve